Iltamiocel is under clinical development by Cook MyoSite and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Iltamiocel’s likelihood of approval (LoA) and phase transition for Hypoactive Bladder took place on 04 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Iltamiocel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Cell therapy is under development for the treatment of fecal incontinence,tongue dysphagia and urological diseases such as stress urinary incontinence and underactive bladder (Hypoactive Bladder). The theraopeuticcandidate is administered through intramuscular route. Autologous muscle-derived cell (AMDCs) possesses a high myogenic capacity and effectively regenerates both skeletal and cardiac muscle. It was also under development for advanced ischemic heart failure. It is formulated as solution for stress urinary incontinence
Quick View Iltamiocel LOA Data
|Highest Development Stage|